Zoetis Expands Poulvac Bron GA08 Label to Address DMV/1639 Infectious Bronchitis Strain

Expanded U.S. vaccine label adds another option for poultry producers confronting evolving infectious bronchitis virus pressure

14 October 2026 | Poultry health | United States

Zoetis has received expanded U.S. label approval for Poulvac® Bron GA08, adding a claim for protection against the DMV/1639 strain of infectious bronchitis virus (IBV). The update is significant for poultry producers and veterinarians seeking to adapt vaccination programmes to the changing strains circulating in U.S. commercial flocks.

Two strain targets, different administration routes

The expanded label reportedly allows Poulvac Bron GA08 to be used in healthy chickens from one day of age. The vaccine addresses two infectious bronchitis types through different administration methods:

• Georgia 2008 (GA08) type: coarse-spray administration

• DMV/1639 type: oral-droplet administration

The updated label gives poultry health teams another vaccination option in response to IBV strain diversity. The product was originally licensed as a live Georgia-type infectious bronchitis vaccine. USDA Animal and Plant Health Inspection Service (APHIS) records confirm Poulvac Bron GA08’s established product identity; the new DMV/1639 label claim is the subject of the October 2026 announcement.

Why DMV/1639 matters

Infectious bronchitis is a highly contagious viral disease of chickens. Depending on the strain and the birds affected, infection can cause respiratory signs, impair performance and affect egg production and egg quality. Some infections can also involve the kidneys. The virus continually evolves, making field surveillance and vaccination strategy important components of flock health management.

DMV/1639—also referred to as Delmarva 1639—has become a prominent concern in U.S. poultry health discussions. This is the predominant field strain addressed by the expanded approval. The practical significance is that vaccine selection can be informed by the strains circulating in a particular production area rather than relying on a static programme indefinitely.

However, the addition of a label claim should not be interpreted as proof that vaccination eliminates infection or transmission under all field conditions. Outcomes depend on vaccine handling, application quality, flock immunity, field-virus pressure, biosecurity and the broader vaccination programme.

Commercial and strategic implications

For integrated poultry companies, infectious bronchitis control is a production-management issue as well as a veterinary one. Respiratory disease, uneven flock performance, secondary complications and egg-production losses can affect operating costs and output. A licensed vaccination option targeting a relevant field strain may therefore have value when veterinarians review regional disease patterns.

For Zoetis, the approval reinforces the role of poultry biologics in a market where virus evolution can sustain demand for updated prevention strategies. The competitive value will depend on adoption by poultry integrators, fit with existing vaccination schedules and evidence of performance in the conditions where the product is used.

Industry takeaway

The expanded Poulvac Bron GA08 label gives U.S. poultry veterinarians an additional reported option for addressing DMV/1639 infectious bronchitis. Producers should consult the current approved label and their flock veterinarian to determine appropriate application, timing and programme compatibility.